Replimune Group Inc
Ownership
Ownership Structure
Who owns Replimune Group Inc (REPL)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.8% of the shares are freely tradable; institutional investors hold 96.9%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Baker Bros Advisors LP | 11.72 | 11,045,336 | +0.0 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 8.62 | 8,121,433 | -1.7 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 7.81 | 7,356,916 | +3.0 | 03/31/2026 |
| BlackRock Inc | 6.62 | 6,239,239 | +2.8 | 03/31/2026 |
| Suvretta Capital Management, LLC | 4.48 | 4,221,836 | +11,615.0 | 03/31/2026 |
| State Street Corp | 4.01 | 3,782,237 | +2.4 | 03/31/2026 |
| FCPM III SERVICES BV | 2.98 | 2,808,368 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.93 | 2,759,120 | +0.0 | 03/31/2026 |
| Logos Global Management LP | 2.65 | 2,500,000 | +0.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.08 | 2,898,583 | -1.1 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Astley-Sparke Philip | Director | 1,362,414 | 17,575,141 $ | Aug 20, 2026 | direct |
| Patel Sushil | Chief Executive Officer | 708,151 | 9,135,148 $ | Aug 10, 2026 | direct |
| Xynos Konstantinos | Chief Medical Officer | 224,215 | 2,892,374 $ | Aug 10, 2026 | direct |
| Hill Emily Luisa | Chief Financial Officer | 215,852 | 2,784,491 $ | Aug 17, 2026 | direct |
| Schwendenman Andrew | Chief Accounting Officer | 99,425 | 1,282,583 $ | Aug 10, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Astley-Sparke Philip | Director | Other | 50,000 | 0.00 | – |
| Aug 17, 2026 | Hill Emily Luisa | Chief Financial Officer | Sell | 9,256 | 14.28 | 132,176 |
| Aug 10, 2026 | Patel Sushil | Chief Executive Officer | Sell | 39,341 | 12.97 | 510,253 |
| Aug 10, 2026 | Hill Emily Luisa | Chief Financial Officer | Sell | 11,448 | 12.97 | 148,481 |
| Aug 10, 2026 | Xynos Konstantinos | Chief Medical Officer | Sell | 11,447 | 12.97 | 148,468 |
| Aug 10, 2026 | Schwendenman Andrew | Chief Accounting Officer | Sell | 7,632 | 12.97 | 98,987 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.